Dr. Lei Chen, Founder and CEO of Yikang Biotech, received his Ph.D. from Osaka University, Japan. He served as a Senior Staff Scientist at NIH/NIAID/VRC for over a decade, specializing in vaccine R&D for RSV, HIV, and SARS. He was a key contributor to the world's first structurebased RSV vaccine (DS-Cav1). Dr. Chen holds over 30 patents and has published 45 SCI papers, including 7 in Science and Cell. He is currently leading next-generation RSV vaccine development at Yikang Biotech, with advantages over GSK's AREXVY and Pfizer's ABRYSVO.